Efficacy of second-line ICI combined with TKI among patients with metastatic renal cell carcinoma: a real-world study. Supplementary data

Supplementary Figure
1. Kaplan-Meier curves for patients with ccRCC or non-ccRCC features. A
(PFS2) and B (OS) represented survival outcomes of patents with ccRCC
feature; C (PFS2) and D (OS) represented the survival outcomes of patients
with non-ccRCC feature.

Supplementary Figure
2. Kaplan-Meier curves for patients with second-line ICI plus TKI treatment
(n = 52) in different IMDC risk groups. A (PFS2) and B (OS) represented
survival outcomes of patents in IMDC favorable-, intermediate-, and poor-risk
groups; C (PFS2) and D (OS) represented the survival outcomes of patients in
the intermediate-risk group; E (PFS2) and F (OS) represented the survival
outcomes of patients with different number of risk factors; G (PFS2) and H
(OS) represented the comparasion of survival outcomes of patients with 0-1
and ≥2 risk factors.

Supplementary Table
1. Univariate analysis of PFS and OS in mRCC patients (n = 110).

Supplementary Table
2. Correlations of genomic mutations with survival outcome in mRCC patients
with ICI plus TKI treatment (n = 52)

Supplementary Table
3. Univariate analysis of PFS2 and OS in mRCC patients with ICI plus TKI
treatment (n = 52)